Abstract
The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Current Psychopharmacology
Title: Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Volume: 1
Author(s): Xiuping Chen, Jiajie Guo, Jiaolin Bao, Wenshan Xu, Yanjuan Huang and Yitao Wang
Affiliation:
Keywords: Neuroprotective agent screening model, PC12, Oxidative stress, SCREENING MODELS, hydrogen peroxide, mitochondrial, Rotenone, Okadaic Acid, prostaglandin, antiepileptic, hypoxia-reoxygenation, mebudipine, ginsenoside, hippocampal, neurotoxins
Abstract: The epidemic of neurodegenerative diseases, such as Alzheimers disease, Parkinsons disease, and cerebral ischemia (e.g., stroke), has long been a worldwide health and social concern with the rapid increase of aging population. To date, efficient therapeutic drugs are still insufficient, making the treatment of these diseases a big challenge to both basic researchers and clinical physicians. A few in vitro and in vivo experimental models are established to explore, as well as evaluate, protective and therapeutic agents. Among these models, cell-based screening models play an important role in the initial step of searching and identifying neuroprotective compounds. Primary cultured hippocampal and cortical neurons, as well as PC12 and SH-SY5Y cells, are among the frequently applied cells in these models. PC12 is an immortalized pheochromocytoma cell line that provides a series of classical screening models by applying a variety of neurotoxins, such as 6-hydroxydopamine, beta amyloid, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and paraquat, among others. In the present review, several neuroprotective and injury models induced by 4-hydroxynonenal, ethanol, high glucose, homocysteine, okadaic acid, rotenone, and oxygen-glucose deprivation, as well as documented protective agents, are discussed.
Export Options
About this article
Cite this article as:
Chen Xiuping, Guo Jiajie, Bao Jiaolin, Xu Wenshan, Huang Yanjuan and Wang Yitao, Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010103
DOI https://dx.doi.org/10.2174/2211556011201010103 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters Glioma Targeting and Anti-glioma Effect of Interleukin 13 Peptide and RGD Peptide Dual Functionalized Nanoparticles
Current Pharmaceutical Biotechnology Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Brain Tumor Detection Using Machine Learning and Deep Learning: A Review
Current Medical Imaging Aquaporins and Roles in Brain Health and Brain Injury
Mini-Reviews in Medicinal Chemistry Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics The Effectiveness of Nanoparticles on Gene Therapy for Glioblastoma Cells Apoptosis: A Systematic Review
Current Gene Therapy Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science